Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
35,097,143
-
Shares change
-
-3,438,455
-
Total reported value, excl. options
-
$445,735,362
-
Value change
-
-$58,506,168
-
Put/Call ratio
-
426%
-
Number of buys
-
71
-
Number of sells
-
41
-
Price
-
$12.70
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2024
As of 30 Sep 2024 UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) had 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 35,097,143 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock, Inc., MENORA MIVTACHIM HOLDINGS LTD., MORGAN STANLEY, COWEN AND COMPANY, LLC, Cormorant Asset Management, LP, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, and UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC.
This table shows 146 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.